Single-cell Analysis Market Size, Share & Trends Analysis Report By Product (Consumables, Instruments), By Application (Cancer, Immunology), By Workflow, By End-user, By Region, And Segment Forecasts, 2022 - 2030

Report Overview

The global single-cell analysis market size was valued at USD 3.28 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 18.5% from 2022 to 2030. The rising prevalence of cancer worldwide and rapid development of technologies have cascaded huge investments from life sciences companies and government funding initiatives for research activities. The research and development (R&D) in the field of medical and clinical diagnostics, the availability of advanced technologies such as sequencing, and the increasing adoption of single-cell analysis devices to understand the central dogma of molecular biology are some of the factors that are contributing to the growth of the market.

The ongoing COVID-19 pandemic positively impacted the market for single-cell analysis (SCA). The pandemic has triggered the widespread adoption of SCA methods in virology research. To understand the immune response and the long-term effects of infections, researchers are utilizing the specimens from COVID-19 biobanks for performing analysis to comprehend the profiles of infected patients. For instance, in March 2021, the researchers from The NHLBI LungMap Consortium and The Human Cell Atlas Lung Biological Network performed a single-cell meta-analysis in 1,320,896 cells from 228 humans. This study was aimed at understanding the entry genes of SARS-CoV-2 across demographics.

The demand for SCA is growing in omics research activities, including genomics, proteomics, transcriptomics, and metabolomics. The study of single-cell omics helps in the analysis of huge data sets and understanding the genetic basis. It is the key to mastering the advancement in human health via disease diagnosis and drug discovery. The technological development has resulted in high throughput assays, efficient cell sorting and tagging, sequencing, microfluidics, single-cell amplification, and advanced software tools. The availability of these products and vast application areas are organically increasing the revenue of this market.

The growing demand for analytical tools for innovative research and subsequent funding has led to the introduction of high-throughput equipment within the market. Multiple innovations have led this equipment to involve features such as automation, high sensitivity, and accuracy, which ultimately help in analyzing scarce samples. For example, in March 2022, Deepcell Inc., a U.S.-based company, received funding of USD 73 million to accelerate its AI-powered single cell analysis platform and move towards commercialization. Thus, key players are significantly investing in developing solutions leading to a lucrative opportunity for revenue generation in the upcoming years. However, the market penetration will face hindrance due to the high cost of these instruments and consumables. The continuous maintenance costs and other expenses related to these products will create constraints for several clinical and research applications with budget limitations.

Product Insights

The consumables segment held the largest revenue share of over 50.0% in 2021 and is projected to exhibit a significant CAGR from 2022 to 2030 owing to the high usability of isolation products, large-scale adoption of cell sorting beads, frequent purchase of buffers and reagents, and growing demand for assay kits. An increase in the prevalence of target diseases and the constant need for consumables required for the assays during scientific activities are propelling the segment growth. Moreover, the extensive use of consumables such as reagents throughout SCA assays creates a continuous high demand for these products. These reagents are available in different forms including probes, cellular markers, multicolor cocktails, and even phenotyping agents. The robust activities of scientific entities have resulted in the massive adoption and purchase of reagents, thus leading to revenue generation in the global market.

The installation of new instruments, replacement of old instruments, and services related to instruments led to revenue generation for the instruments segment. Owing to the high-end features and the technically advanced analytical options, the automated instruments are anticipated to witness significant growth during the forecast period.

Application Insights

The cancer segment captured the largest revenue share of over 30.0% in 2021. Single-cell analysis has proved to be effective for the diagnosis of cancer cells. The genetic variation via cell proliferation conditions, mutation rates, and cell types can be easily identified using these techniques. As per the American Cancer Society, cancer is the second most common cause of death in the U.S. after heart disease. According to cancer statistics, in 2022, 1.9 million new cancer cases are expected to occur in the U.S. Thus, the increasing prevalence of cancer and the never-ceasing studies and developments in this field are anticipated to positively impact the industry growth.

The existence of a significant number of research activities for evaluating single-cell genomics and proteomics has led to the increasing implementation of SCA methods in therapeutic and diagnostics applications. Moreover, increasing demand for stem cell therapies for regenerative and personalized medicines is bolstering this market space. Therapies like regeneration of hair, transplants of tissue, and organ and bone marrow are boosting the usage rates of single-cell analysis techniques.

Workflow Insights

In 2021, the single cell isolation and library preparation segment accounted for the largest revenue share of over 35.0%. The vast range of applications for SCA has subsequently increased the demand for cell isolation and library preparation products such as kits and reagents. In addition, a substantial number of industry players are offering a range of products for single-cell isolation, to name a few, FACS and MACS for heterogeneous cell suspensions, microdissection of fixed tissue samples, flow cytometry, and microfluidics, in this segment, in turn, augmenting the revenue growth.

The downstream analysis segment is gaining traction owing to the technological advancements over the past few years. Technologies such as the emergence of next-generation sequencing for analyzing cellular expressions, mass spectrometry, and FISH (Fluorescence in situ hybridization) have proven to be important tools for SCA. Also, the market is witnessing the increasing automation of machines and artificial intelligence for data analysis. Several software and computational methods have been developed and are being employed due to their benefits such as scalability, flexibility, and high success rates. For example, as of 2021, there were over 1000 single-cell RNA analysis tools. Thus, this high growth of database tools reflects the interest and availability of SCA technologies, which, in turn, will spur industry growth in the near future.

End-user Insights

The academic and research laboratories accounted for the largest revenue share of over 70.0% in 2021 due to the wide use of single-cell analysis technology in research settings. The considerable number of ongoing scientific projects at various universities employing SCA techniques has driven its adoption in 2021. The introduction of spatial genomics accelerates the single-cell analysis in research activities, which is another key factor driving the segment. Furthermore, developing new tools to tackle the research limitation is driving the market, for example, researchers at Stony Brook University, New York developed a new biomedical research tool, single-cell cyclic multiplex in situ tagging (CycMIST) technology in June 2022. This technology enables scientists to assess functional proteins in a single cell and contribute to the diagnostic and discovery fields.

Technological progressions such as the use of microfluidics for the development of cell and gene therapies have increased the adoption of SCA by biotechnology and pharmaceutical companies. Moreover, increasing penetration of multi-omics in drug development research would further drive the market. A substantial number of firms have invested in genomics to have an access to various genomics databases. For instance, Lifebit, a U.K.-based big data company, announced partnering with Boehringer Ingelheim in March 2022. The partnership will make use of the Cloud OS of Lifebit, the first federated platform for genomics to build a data analytics infrastructure for Boehringer. This infrastructure will capture disease insights from biobanks for the development of medicines. Boehringer was also associated with Lifebit’s REAL platform in 2021 to accelerate the detection and tracking of disease outbreaks.

Regional Insights

North America dominated the global market with a revenue share of over 35.0% in 2021. This can be attributed to factors such as multiple government funding programs, rising awareness regarding personal healthcare and related expenditure, faster adoption of novel analytical tools and techniques, and the availability of trained personnel. The U.S. is a major contributor to the industry growth in North America. For example, the U.S. NIH (National Institutes of Health) through its Common Fund Programs is supporting metabolomics research. Formerly, the NIH had also supported the single cell analysis program (SCAP) through the same funds. Extraordinary healthcare infrastructure, demand for personalized medicines, and the presence of key market players are some of the key factors fueling regional growth.

Asia Pacific is expected to exhibit the fastest CAGR over the forecast period. In the past years, the growing medical industry, rapidly developing healthcare systems, and increasing geriatric population have resulted in fueling the demand for cutting-edge diagnostic tools in the emerging economies of Asia Pacific. The focused efforts and outsourcing in this region have led to significant growth.

Key Companies & Market Share Insights

The market for single cell analysis has been endlessly growing over the past few years owing to the increasing upswing of single cell analysis techniques for therapeutic and diagnostic applications. The prevalence of genetic disorders has resulted in the increasing need for early diagnosis and better treatments. This has created worthwhile opportunities for emerging players to capture untapped opportunities. These emerging companies have focused on the development of innovative and technologically advanced products to fulfill consumer demand. For instance, in February 2021, SeqWell Inc. announced the launch of the plexWell Single Cell Rapid Kit. The kit can be used for single-cell RNA sequencing and simplified preparation of NGS libraries. Further, the company has signed a distribution agreement with CELLINK AB in February 2021 for the commercialization of its products to expand its presence outside the U.S.

Developed and matured market players are expanding their market presence and product portfolios by acquisitions and partnership business models. For example, in January 2022, BD Biosciences, a part of Becton, Dickinson & Company, acquired CytognosS.L., a Spain-based biotech company that offers flow cytometry solutions. This acquisition has helped BD expand its flow cytometry portfolio for cancer diagnostics and clinical research. Such company initiatives are expected to intensify market competition. Some prominent players in the global single cell analysis market include:

• Thermo Fisher Scientific, Inc.

• QIAGEN NV

• Bio-Rad Laboratories Inc.

• Illumina Inc.

• Merck KGaA

• Becton, Dickinson & Company

• Fluidigm Corporation

• 10x Genomics, Inc.

• BGI

• Novogene Corporation

Single-cell Analysis Market Report Scope

Global Single-cell Analysis Market Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the global single-cell analysis market report based on product, application, workflow, end-user, and region:

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Consumables

    • Reagents

    • Assay Kits

  • Instruments

    • Manual Instruments

    • Microscopes

    • Hemocytometers

    • Automated Instruments

    • Flow Cytometers

    • Next Generation Sequencing

    • PCR Systems

    • High-content Screening System

    • Cell Microarrays

    • Automated Cell Counters

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Cancer

  • Immunology

  • Neurology

  • Stem Cell

  • Non-invasive Prenatal Diagnosis

  • In-vitro Fertilization

  • Others

• Workflow Outlook (Revenue, USD Million, 2018 - 2030)

  • Single Cell Isolation & Library Preparation

  • Downstream Analysis

  • Data Analysis

• End-user Outlook (Revenue, USD Million, 2018 - 2030)

  • Academic & Research Laboratories

  • Biotechnology & Pharmaceutical Companies

  • Hospitals & Diagnostic Laboratories

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • France

    • Italy

    • Spain

  • Asia Pacific

    • China

    • India

    • Japan

    • South Korea

  • Latin America

    • Brazil

    • Mexico

  • Middle East and Africa

    • South Africa

    • Saudi Arabia